Cyclo Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Cyclo Therapeutics's earnings have been declining at an average annual rate of -23.3%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 4.1% per year.
Belangrijke informatie
-23.3%
Groei van de winst
39.7%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 4.1% |
Rendement op eigen vermogen | n/a |
Nettomarge | -1,831.3% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M
Aug 16Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation
Jul 12We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate
Jan 20Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
Nov 16Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?
Sep 28Cyclo therapeutics to join Russell 2000 Index
Jun 14We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate
Jun 12Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo
Apr 27Opbrengsten en kosten
Hoe Cyclo Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 1 | -21 | 8 | 14 |
31 Mar 24 | 1 | -19 | 8 | 14 |
31 Dec 23 | 1 | -20 | 7 | 14 |
30 Sep 23 | 1 | -19 | 7 | 13 |
30 Jun 23 | 1 | -19 | 7 | 13 |
31 Mar 23 | 1 | -18 | 8 | 11 |
31 Dec 22 | 1 | -15 | 8 | 9 |
30 Sep 22 | 2 | -13 | 8 | 7 |
30 Jun 22 | 2 | -13 | 8 | 6 |
31 Mar 22 | 1 | -13 | 7 | 7 |
31 Dec 21 | 2 | -14 | 7 | 9 |
30 Sep 21 | 1 | -14 | 6 | 9 |
30 Jun 21 | 1 | -12 | 4 | 8 |
31 Mar 21 | 1 | -10 | 4 | 7 |
31 Dec 20 | 1 | -9 | 4 | 6 |
30 Sep 20 | 1 | -9 | 3 | 7 |
30 Jun 20 | 1 | -9 | 3 | 7 |
31 Mar 20 | 1 | -8 | 4 | 6 |
31 Dec 19 | 1 | -8 | 3 | 5 |
30 Sep 19 | 1 | -6 | 3 | 4 |
30 Jun 19 | 1 | -5 | 3 | 4 |
31 Mar 19 | 1 | -5 | 3 | 4 |
31 Dec 18 | 1 | -4 | 2 | 3 |
30 Sep 18 | 1 | -4 | 3 | 3 |
30 Jun 18 | 1 | -4 | 3 | 2 |
31 Mar 18 | 1 | -4 | 3 | 2 |
31 Dec 17 | 1 | -4 | 3 | 2 |
30 Sep 17 | 2 | -3 | 2 | 2 |
30 Jun 17 | 2 | -4 | 3 | 2 |
31 Mar 17 | 1 | -5 | 3 | 2 |
31 Dec 16 | 2 | -4 | 3 | 2 |
30 Sep 16 | 1 | -4 | 3 | 2 |
30 Jun 16 | 1 | -4 | 3 | 1 |
31 Mar 16 | 1 | -3 | 2 | 1 |
31 Dec 15 | 1 | -3 | 2 | 1 |
30 Sep 15 | 1 | -2 | 2 | 0 |
30 Jun 15 | 1 | -1 | 2 | 0 |
31 Mar 15 | 1 | -1 | 2 | 0 |
31 Dec 14 | 2 | -1 | 2 | 0 |
30 Sep 14 | 1 | 0 | 1 | 0 |
30 Jun 14 | 1 | 0 | 1 | 0 |
31 Mar 14 | 2 | 0 | 1 | 0 |
31 Dec 13 | 2 | 0 | 1 | 0 |
Kwaliteitswinsten: CYTH is currently unprofitable.
Groeiende winstmarge: CYTH is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CYTH is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Versnelling van de groei: Unable to compare CYTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CYTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: CYTH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.